NASDAQ$DFTX
Definium Therapeutics Inc · Q1 2025 earnings
Q1 2025 earnings · · After market close · Investor relations
Briefing
MindMed reported Q1 2025 results with a net loss of $19.1M and EPS of -$3.33.
Mind Medicine (MindMed) Inc. posted a Q1 2025 net loss of $19.1 million, or -$3.33 per share, reflecting increased R&D investment. The company ended the quarter with $94.6 million in cash, cash equivalents, and short-term investments, sufficient to fund operations into the first half of 2026.
- Net loss for Q1 2025 was $19.1 million compared to $17.1 million in Q1 2024.
- EPS was -$3.33 compared to -$3.13 in the same quarter last year.
- R&D expense rose to $15.0 million due to advancing clinical programs.
- Cash and short-term investments totaled $94.6 million, expected to fund operations into 1H 2026.
Headline financials
Revenue & EPS history
MindMed · Revenue · Quarterly
$0
Forward guidance
MindMed expects to continue advancing its MM120 and MM402 programs, with multiple data readouts anticipated in the second half of 2025. Cash runway is expected into the first half of 2026.
Tailwinds
- Multiple data readouts expected in 2H 2025.
- Continued progress in MM120 and MM402 clinical programs.
- Sufficient cash runway into 1H 2026.
- Strong pipeline focus on mental health indications.
- Potential for strategic partnerships to support growth.
Headwinds
- Ongoing operating losses due to high R&D spend.
- No revenue from product sales.
- Dependency on clinical trial outcomes for future growth.
- Cash runway only extends into 1H 2026.
- Potential dilution risk if additional financing is required.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2025
+0.8%
Avg return
Earnings day
+2.9%
Avg return
5 days after
+3.0%
Avg return
30 days after
44%
14 / 32 earnings
Positive
+25.8%
Q3 2024
Best reaction
-25.0%
Q1 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +0.9% | +2.7% | +3.4% | |
| Q3 2025 | +3.2% | +7.1% | +8.9% | |
| Q2 2025 | -7.3% | +8.8% | -2.3% | |
| Q1 2025 | +4.4% | +6.5% | +26.2% | |
| Q4 2024 | +3.6% | -0.7% | -14.9% | |
| Q3 2024 | +25.8% | +21.3% | +10.2% | |
| Q1 2024 | -4.5% | -11.5% | -24.1% | |
| Q4 2023 | +2.9% | +12.2% | +69.1% | |
| Q3 2023 | +24.1% | +13.3% | +41.4% | |
| Q2 2023 | -5.2% | -5.4% | -10.5% | |
| Q1 2023 | -7.6% | -10.8% | -6.4% | |
| Q4 2022 | -9.9% | -8.1% | -12.3% | |
| Q3 2022 | +19.9% | +18.7% | +9.5% | |
| Q2 2022 | +11.3% | +4.3% | -15.0% | |
| Q1 2022 | -0.8% | -1.2% | -2.3% | |
| Q4 2021 | +0.0% | -9.3% | -30.9% | |
| Q4 2020 | -7.0% | -7.7% | -5.8% | |
| Q3 2020 | +8.2% | +13.3% | +28.8% | |
| Q2 2020 | +14.9% | +5.7% | -9.2% | |
| Q1 2020 | +4.5% | -5.2% | +2.0% | |
| Q3 2019 | -13.7% | -13.7% | +29.4% | |
| Q2 2019 | +0.0% | +33.3% | +11.1% | |
| Q1 2019 | -25.0% | +38.3% | -1.7% | |
| Q4 2018 | -1.9% | -3.7% | +11.1% | |
| Q3 2018 | -4.2% | +4.2% | -12.5% | |
| Q2 2018 | -0.9% | -6.0% | -39.6% | |
| Q1 2018 | -8.4% | -9.8% | -15.8% | |
| Q4 2017 | -4.4% | +0.0% | +2.4% | |
| Q3 2017 | +1.6% | +9.6% | -2.7% | |
| Q2 2017 | -1.9% | -7.5% | -0.4% | |
| Q1 2016 | +1.5% | -6.4% | -10.1% | |
| Q4 2016 | +0.0% | +0.0% | +58.2% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro